The rise of ampicillin-resistant Enterococcus faecium high-risk clones as a frequent intestinal colonizer in oncohaematological neutropenic patients on levofloxacin prophylaxis: a risk for bacteraemia?

Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
Ana María Sánchez-DíazP Ruiz-Garbajosa

Abstract

Levofloxacin extended prophylaxis (LEP), recommended in oncohaematological neutropenic patients to reduce infections, might select resistant bacteria in the intestine acting as a source of endogenous infection. In a prospective observational study we evaluated intestinal emergence and persistence of ampicillin-resistant Enterococcus faecium (AREfm), a marker of hospital adapted high-risk clones. AREfm was recovered from the faeces of 52 patients with prolonged neutropenia after chemotherapy, at admission (Basal), during LEP, and twice weekly until discharge (Pos-LEP). Antibiotic susceptibility, virulence traits and population structure (pulsed-field gel electrophoresis and multilocus sequence typing) were determined and compared with bacteraemic isolates. Gut enterococcal population was monitored using a quantitative PCR quantification approach. AREfm colonized 61.4% of patients (194/482 faecal samples). Sequential AREfm acquisition (25% Basal, 36.5% LEP, 50% Pos-LEP) and high persistent colonization rates (76.9-89.5%) associated with a decrease in clonal diversity were demonstrated. Isolates were clustered into 24 PFGE-patterns within 13 sequence types, 95.8% of them belonging to hospital-associated Bayesian analysis of popula...Continue Reading

References

Oct 1, 1996·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J P SuppolaM Vaara
Mar 26, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Stefan ReuterHeike von Baum
Nov 2, 2006·The Journal of Antimicrobial Chemotherapy·Anat Gafter-GviliLeonard Leibovici
Mar 30, 2007·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·J TopM Bonten
Jun 12, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Michel J van VlietHermie J M Harmsen
Jan 6, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Alison G Freifeld Infectious Diseases Society of Americaa
Jan 25, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Alison G Freifeld Infectious Diseases Society of America
Feb 18, 2011·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Yong ChongTomohiko Kamimura
Jul 27, 2011·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·P Ruiz-GarbajosaR J L Willems
Jun 22, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ying TaurEric G Pamer
Aug 31, 2013·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Ana María Sánchez-DíazPatricia Ruiz-Garbajosa

❮ Previous
Next ❯

Citations

Sep 23, 2016·The Journal of Antimicrobial Chemotherapy·Ana P TedimTeresa M Coque
Mar 17, 2018·The Journal of Antimicrobial Chemotherapy·Theodore GouliourisSharon J Peacock
Sep 22, 2021·CA: a Cancer Journal for Clinicians·Amila K NanayakkaraDavid E Greenberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.